Arnaoutakis, Konstantinos
Wan, Yin
Elliott, Jennifer
Young, Matt
Yin, Yu
Leventakos, Konstantinos
Lin, Huamao M.
Dimou, Anastasios
Article History
Received: 14 March 2024
Accepted: 10 May 2024
First Online: 25 June 2024
Declarations
:
: Konstantinos Arnaoutakis: Consulting activities: Gilead, OncLive/MJH Life Sciences; stocks: Athos Therapeutics. Yin Wan: Employment (Takeda). Jennifer Elliott: Employment (Takeda). Matt Young: Employment (Takeda). Yu Yin: Employment (Takeda). Konstantinos Leventakos: Consulting activities: Boehringer Ingelheim, Amgen, AstraZeneca, Targeted Oncology, Takeda, Jazz Pharmaceuticals, Mirati Therapeutics, Janssen, and Regeneron; research support (to institution): AstraZeneca and Mirati Therapeutics; CME activities: OncLive and MJH Life Sciences. Huamao M. Lin: Employment (Takeda). Anastasios Dimou: Advisory board: TP Therapeutics, AnHeart Therapeutics, Guardant Health, and ChromaCode; clinical trial support: Syntrix Pharmaceuticals, Novartis, Sorrento Therapeutics, AnHeart Therapeutics, Merck, and Guardant Health; honoraria: Roche/Genentech.
: This was a retrospective cohort study of real-world data obtained from Flatiron Health OncoEMR, a longitudinal electronic health record database consisting of de-identified patient-level structured and unstructured data curated through technology-enabled chart abstraction from more than 280 cancer clinics in the USA. Secondary use of de-identified patient data is exempted from ethics review and informed consent according to the Department of Health and Human Services regulation 45 CFR 46.104(d)(4).